These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38750176)

  • 1. Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice.
    Liu Y; Wong CC; Ding Y; Gao M; Wen J; Lau HC; Cheung AH; Huang D; Huang H; Yu J
    Nat Microbiol; 2024 Jun; 9(6):1467-1482. PubMed ID: 38750176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity.
    Long X; Wong CC; Tong L; Chu ESH; Ho Szeto C; Go MYY; Coker OO; Chan AWH; Chan FKL; Sung JJY; Yu J
    Nat Microbiol; 2019 Dec; 4(12):2319-2330. PubMed ID: 31501538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the mechanism of
    Gu J; Lv X; Li W; Li G; He X; Zhang Y; Shi L; Zhang X
    Front Immunol; 2023; 14():1230681. PubMed ID: 37781363
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant NAFLD Facilitates Liver Metastases and PD-1-Refractory by Recruiting MDSCs via CXCL5/CXCR2 in Colorectal Cancer.
    Yang Y; Chen Y; Liu Z; Chang Z; Sun Z; Zhao L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101351. PubMed ID: 38724007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer.
    Chen J; Sun HW; Yang YY; Chen HT; Yu XJ; Wu WC; Xu YT; Jin LL; Wu XJ; Xu J; Zheng L
    Signal Transduct Target Ther; 2021 Jan; 6(1):4. PubMed ID: 33414378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
    Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
    Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice.
    Tsoi H; Chu ESH; Zhang X; Sheng J; Nakatsu G; Ng SC; Chan AWH; Chan FKL; Sung JJY; Yu J
    Gastroenterology; 2017 May; 152(6):1419-1433.e5. PubMed ID: 28126350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
    Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
    Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
    Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
    J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications.
    Tong X; Qiao S; Dong Z; Zhao X; Du X; Niu W
    J Nanobiotechnology; 2024 Jul; 22(1):409. PubMed ID: 38992688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability.
    Roh SA; Kwon YH; Lee JL; Kim SK; Kim JC
    Anticancer Res; 2021 Nov; 41(11):5431-5444. PubMed ID: 34732412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
    Cao L; Dai C; Qin R; Guo Y; Liu J
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
    [No Abstract]   [Full Text] [Related]  

  • 18. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
    Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
    Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A9 Regulates MDSCs-Mediated Immune Suppression via the RAGE and TLR4 Signaling Pathways in Colorectal Carcinoma.
    Huang M; Wu R; Chen L; Peng Q; Li S; Zhang Y; Zhou L; Duan L
    Front Immunol; 2019; 10():2243. PubMed ID: 31620141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.